|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7423050||ELI LILLY AND CO||Pyridinoylpiperidines as 5-HT1F agonists|| |
(4 years from now)
|US11053214||ELI LILLY AND CO||Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists|| |
(14 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8748459||ELI LILLY AND CO||Pyridinoylpiperidines as 5-HT1F agonists|| |
(5 months ago)
Reyvow is owned by Eli Lilly And Co.
Reyvow contains Lasmiditan Succinate.
Reyvow has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Reyvow are:
Reyvow was authorised for market use on 31 January, 2020.
Reyvow is available in tablet;oral dosage forms.
Reyvow can be used as acute treatment of migraine.
Drug patent challenges can be filed against Reyvow from 2024-02-01.
The generics of Reyvow are possible to be released after 05 December, 2037.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Jan 31, 2025|
NCE-1 date: 2024-02-01
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic